These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 18848893

  • 21. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A, Muşat A, Doscan A, Bari M, Zapucioiu C, Urdea E, Cochior D, Peţa D.
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [Abstract] [Full Text] [Related]

  • 22. Fabry disease.
    Toyooka K.
    Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
    [Abstract] [Full Text] [Related]

  • 23. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP.
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [Abstract] [Full Text] [Related]

  • 24. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
    Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, Rodriguez M, Desnick RJ.
    Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
    [Abstract] [Full Text] [Related]

  • 25. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
    Ishii S, Chang HH, Yoshioka H, Shimada T, Mannen K, Higuchi Y, Taguchi A, Fan JQ.
    J Pharmacol Exp Ther; 2009 Mar; 328(3):723-31. PubMed ID: 19106170
    [Abstract] [Full Text] [Related]

  • 26. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.
    Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT.
    Circulation; 2005 Feb 08; 111(5):629-32. PubMed ID: 15668341
    [Abstract] [Full Text] [Related]

  • 27. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
    Bangari DS, Ashe KM, Desnick RJ, Maloney C, Lydon J, Piepenhagen P, Budman E, Leonard JP, Cheng SH, Marshall J, Thurberg BL.
    Am J Pathol; 2015 Mar 08; 185(3):651-65. PubMed ID: 25553976
    [Abstract] [Full Text] [Related]

  • 28. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
    Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, Han KH, Jung SC, Suh SH.
    Cardiovasc Res; 2011 Feb 01; 89(2):290-9. PubMed ID: 20971723
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
    Lee CJ, Fan X, Guo X, Medin JA.
    J Cardiol; 2011 Jan 01; 57(1):115-22. PubMed ID: 20846825
    [Abstract] [Full Text] [Related]

  • 32. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI, Zhou Q, Sørensen SS, Rasmussen AK, Jacobsen C, Feldt-Rasmussen U, Nielsen R.
    J Am Soc Nephrol; 2007 Mar 01; 18(3):698-706. PubMed ID: 17287429
    [Abstract] [Full Text] [Related]

  • 33. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
    Katayama M, Kobayashi T, Ohnishi A, Goto I, Kuroiwa Y.
    Rinsho Shinkeigaku; 1984 Jun 01; 24(6):575-80. PubMed ID: 6094070
    [No Abstract] [Full Text] [Related]

  • 34. [Anderson-Fabry disease].
    Kes P, Basić-Jukić N, Brunetta B, Jurić I.
    Acta Med Croatica; 2006 Jun 01; 60(1):55-8. PubMed ID: 16802573
    [Abstract] [Full Text] [Related]

  • 35. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
    Drel VR, Mashtalir N, Ilnytska O, Shin J, Li F, Lyzogubov VV, Obrosova IG.
    Diabetes; 2006 Dec 01; 55(12):3335-43. PubMed ID: 17130477
    [Abstract] [Full Text] [Related]

  • 36. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K, Hirai Y, Ishizaki M, Takahashi H, Hanawa H, Fukunaga Y, Shimada T.
    Mol Genet Metab; 2009 Mar 01; 96(3):91-6. PubMed ID: 19091614
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH, Zuber C, Roth J.
    FASEB J; 2005 Jan 01; 19(1):12-8. PubMed ID: 15629890
    [Abstract] [Full Text] [Related]

  • 39. Renal involvement in Anderson-Fabry disease.
    Sessa A, Meroni M, Battini G, Righetti M, Maglio A, Tosoni A, Nebuloni M, Vago G, Giordano F.
    J Nephrol; 2003 Jan 01; 16(2):310-3. PubMed ID: 12774774
    [Abstract] [Full Text] [Related]

  • 40. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.
    Cilmi SA, Karalius BJ, Choy W, Smith RN, Butterton JR.
    J Infect Dis; 2006 Oct 15; 194(8):1135-40. PubMed ID: 16991089
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.